Atara Biotherapeutics Stock Performance
| ATRA Stock | USD 6.82 0.19 2.87% |
The firm shows a Beta (market volatility) of 1.12, which signifies a somewhat significant risk relative to the market. Atara Biotherapeutics returns are very sensitive to returns on the market. As the market goes up or down, Atara Biotherapeutics is expected to follow. At this point, Atara Biotherapeutics has a negative expected return of -0.69%. Please make sure to confirm Atara Biotherapeutics' coefficient of variation, value at risk, rate of daily change, as well as the relationship between the total risk alpha and kurtosis , to decide if Atara Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Atara Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.63) | Five Day Return (5.96) | Year To Date Return (53.18) | Ten Year Return (99.32) | All Time Return (97.51) |
Last Split Factor 1:25 | Last Split Date 2024-06-20 |
1 | ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate | 01/17/2025 |
2 | Acquisition by Eric Hyllengren of 34050 shares of Atara Biotherapeutics subject to Rule 16b-3 | 01/27/2025 |
3 | Wolf Haldenstein Adler Freeman Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws | 02/03/2025 |
4 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 02/07/2025 |
5 | LB Pharmaceuticals Announces Key Executive Appointments to Support Growth and Late-Stage Development of LB-102 | 02/11/2025 |
6 | Geron Reports Q4 Loss, Tops Revenue Estimates | 02/26/2025 |
7 | Praxis Precision Medicines, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/28/2025 |
8 | Disposition of 1059 shares by Jill Henrich of Atara Biotherapeutics at 6.997 subject to Rule 16b-3 | 03/05/2025 |
9 | Atara Biotherapeutics Releases Earnings Results, Beats Estimates By 2.63 EPS | 03/07/2025 |
10 | Acquisition by Fust Matthew K of 79500 shares of Atara Biotherapeutics at 1.53 subject to Rule 16b-3 | 03/13/2025 |
| Begin Period Cash Flow | 26 M |
Atara |
Atara Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 1,333 in Atara Biotherapeutics on December 24, 2024 and sell it today you would lose (670.00) from holding Atara Biotherapeutics or give up 50.26% of portfolio value over 90 days. Atara Biotherapeutics is currently does not generate positive expected returns and assumes 9.1512% risk (volatility on return distribution) over the 90 days horizon. In different words, 81% of stocks are less volatile than Atara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atara Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atara Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atara Biotherapeutics, and traders can use it to determine the average amount a Atara Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0755
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATRA |
Estimated Market Risk
| 9.15 actual daily | 81 81% of assets are less volatile |
Expected Return
| -0.69 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Atara Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atara Biotherapeutics by adding Atara Biotherapeutics to a well-diversified portfolio.
Atara Biotherapeutics Fundamentals Growth
Atara Stock prices reflect investors' perceptions of the future prospects and financial health of Atara Biotherapeutics, and Atara Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atara Stock performance.
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (0.66) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 40.77 M | ||||
| Shares Outstanding | 5.86 M | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.30 X | ||||
| Revenue | 128.94 M | ||||
| Gross Profit | (39.8 M) | ||||
| EBITDA | (75.75 M) | ||||
| Net Income | (85.4 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 29.91 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (16.60) X | ||||
| Cash Flow From Operations | (68.72 M) | ||||
| Earnings Per Share | (11.41) X | ||||
| Market Capitalization | 38.84 M | ||||
| Total Asset | 109.1 M | ||||
| Retained Earnings | (2.05 B) | ||||
| Working Capital | (69.68 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
About Atara Biotherapeutics Performance
By analyzing Atara Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Atara Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Atara Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Atara Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 185.11 | 124.70 | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | 3.28 | 3.44 | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | 0.88 | 0.92 |
Things to note about Atara Biotherapeutics performance evaluation
Checking the ongoing alerts about Atara Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atara Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atara Biotherapeutics generated a negative expected return over the last 90 days | |
| Atara Biotherapeutics has high historical volatility and very poor performance | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 128.94 M. Net Loss for the year was (85.4 M) with loss before overhead, payroll, taxes, and interest of (39.8 M). | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (68.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Acquisition by Fust Matthew K of 79500 shares of Atara Biotherapeutics at 1.53 subject to Rule 16b-3 |
- Analyzing Atara Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atara Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Atara Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atara Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atara Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atara Biotherapeutics' stock. These opinions can provide insight into Atara Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |